Epigenetic histone modification by butyrate downregulates KIT and attenuates mast cell function

Area of Science:

• Immunology
• Epigenetics
• Gastroenterology

Background:

• Mast cells (MCs) are key players in allergic inflammation and asthma.
• Stem cell factor (SCF) signaling through KIT receptor regulates MC survival and proliferation.
• Butyrate is known to reduce lung inflammation in asthma models, but its mechanism on MCs is unclear.

Purpose of the Study:

• To elucidate the mechanism by which butyrate influences SCF signaling in mast cells.
• To investigate the role of histone modification and HDAC inhibition in butyrate's effects on MCs.
• To evaluate butyrate's potential as a therapeutic agent for asthma and allergies.

Main Methods:

• Treatment of mast cells with butyrate and assessment of histone modifications (acetylation, butyrylation) and HDAC activity.
• Analysis of SCF receptor KIT expression and phosphorylation.
• Evaluation of downstream signaling pathways (p38, Erk) and pro-inflammatory cytokine secretion.
• Pharmacological inhibition of Class I HDAC (HDAC1/3) to compare effects with butyrate.

Main Results:

• Butyrate treatment induced histone modifications and inhibited HDAC activity in mast cells.
• Butyrate downregulated KIT expression and phosphorylation, attenuating SCF-mediated MC proliferation and cytokine release.
• Butyrate's inhibitory effects on MC function were mediated via epigenetic histone modification and HDAC inhibition, not through GPR41/GPR43 receptors.
• Pharmacological inhibition of HDAC1/3 mimicked butyrate's effects on MCs.

Conclusions:

• Butyrate epigenetically modulates mast cell function by inhibiting HDACs and downregulating the SCF/KIT signaling axis.
• These epigenetic alterations lead to suppressed mast cell proliferation and pro-inflammatory cytokine secretion.
• Butyrate supplementation represents a promising therapeutic strategy for allergy and asthma through epigenetic modification of mast cells.